Neuren Pharmaceuticals Sees Surge in H1 Revenue
Company Announcements

Neuren Pharmaceuticals Sees Surge in H1 Revenue

Neuren Pharmaceuticals Limited (AU:NEU) has released an update.

Neuren Pharmaceuticals reports a significant increase in H1 2024 royalty income to A$24.3 million, an upsurge from A$3.5 million in H1 2023, with a profit after tax of A$8.0 million. The company’s cash and short-term investments stand at A$213 million, reflecting a strong financial position. Neuren also anticipates robust full-year revenue from DAYBUE™ of A$132-138 million, highlighting successful Phase 2 trials of NNZ-2591 for treating neurodevelopmental disorders.

For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskNeuren Pharmaceuticals Posts Sharp Profit Decline
TipRanks Australian Auto-Generated NewsdeskNeuren Aims to Transform Neurodevelopmental Care
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App